Vaccination of metastatic prostate cancer patients using mature dendritic cells transfected with mRNA encoding hTERT or an MHC class II targeted hTERT/LAMP fusion protein: Results from a phase I clinical trial

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 2507-2507 ◽  
Author(s):  
Z. Su ◽  
J. W. Vieweg ◽  
J. Dannull ◽  
P. Dahm
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
Dendritic Cells ◽  
Fusion Protein ◽  
Phase I ◽  
Cancer Patients ◽  
Mhc Class Ii ◽  
Metastatic Prostate Cancer ◽  
Class Ii ◽  
Phase I Clinical Trial

Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial

The Prostate ◽  
2006 ◽  
Vol 66 (8) ◽  
pp. 811-821 ◽  
Author(s):  
Susanne Fuessel ◽  
Axel Meye ◽  
Marc Schmitz ◽  
Stefan Zastrow ◽  
Clemens Linné ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
Dendritic Cells ◽  
Phase I ◽  
Cancer Patients ◽  
Phase I Clinical Trial ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

Early results of a phase I clinical trial of an Ii-Key/HER2/neu MHC Class II peptide-based vaccine in breast cancer patients

2006 ◽  
Vol 203 (3) ◽  
pp. S81 ◽  
Author(s):  
Steven Khoo ◽  
Catherine Storrer ◽  
Katie Harris ◽  
Yusuf Jama ◽  
Anna Smith ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Phase I ◽  
Cancer Patients ◽  
Mhc Class Ii ◽  
Class Ii ◽  
Phase I Clinical Trial ◽  
Breast Cancer Patients ◽  
Early Results

Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 2551-2551
Author(s):  
A. Meye ◽  
S. Fuessel ◽  
M. Schmitz ◽  
S. Zastrow ◽  
C. Linne ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
Dendritic Cells ◽  
T Cell ◽  
Phase I ◽  
T Cell Activation ◽  
T Cell Response ◽  
Phase I Clinical Trial ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

2551 Background: For patients with hormone-refractory prostate cancer (HRPC) treatment options are limited. Immunotherapies based on dendritic cells (DCs) might represent promising alternatives. In a Phase I clinical trial, we evaluated the safety and feasibility of a vaccination with monocyte-derived DCs loaded with a cocktail consisting of HLA-A*0201-restricted peptides derived from prostate cancer-associated antigens (PSA, PSMA, survivin, prostein, trp-p8). Methods: Eight HRPC patients were enrolled in this study (Table). Each patient underwent two leukaphereses, for the isolation of monocytes and subsequent generation of mature DCs. Patients received a total of four vaccinations each with peptide cocktail-loaded DCs at a dose of 1 x 107 cells both intradermally and intravenously every other week. Clinical response was monitored by the determination of the PSA level. The induction of a peptide-specific T-cell response was assessed by ELISPOT analysis. Results: Apart from local erythema and edema at the site of intradermal administration no side effects were noted. Four of eight patients showed a temporary PSA decline. One patient displayed a partial response with a PSA decrease > 50% for seven weeks and further stabilization for five weeks. Stable PSA values or decelerated PSA increases were observed in the three remaining patients. In ELISPOT analyses, three of four PSA responders also showed antigen-specific CD8+ T-cell activation against prostein, survivin and PSMA. Conclusions: The described protocol represents a safe and feasible concept for the induction of clinical and immunological responses. The application of a peptide cocktail derived from different antigens as a novel treatment modality is supposed to allow for the genetic and biologic heterogeneity of PCa. [Table: see text] [Table: see text]

Abstract A16: A phase I/II clinical trial of a MUC1-glycopeptide dendritic cell vaccine in castrate resistant non-metastatic prostate cancer patients

2012 ◽  
Vol 72 (4 Supplement) ◽  
pp. A16-A16 ◽  
Author(s):  
Pierre Major ◽  
Louis Lacombe ◽  
Yves Fradet ◽  
Ronan Foley ◽  
Elizabeth Scheid ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
Dendritic Cell ◽  
Phase I ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer ◽  
Dendritic Cell Vaccine ◽  
Cell Vaccine ◽  
Castrate Resistant
Sign in / Sign up

Export Citation Format

Share Document